ABSTRACT
O uso de promotores de crescimento na alimentação de animais tem sofrido grandes mudanças na União Européia. Empregados com sucesso há mais de 50 anos, estes aditivos foram banidos na Europa em 2006, o que intensificou as pesquisas para descobrir produtos alternativos. Já estão em uso com bons resultados na alimentação de aves, suínos e bovinos os pro-bióticos e as leveduras. Ultimamente, certos tipos de óleos demonstraram interferir na fermentação do rúmen produzindo mais ácidos gráxos.
Subject(s)
Animals , Cattle , Functional Food , Growth and Development , Plant Oils/analysis , Oils, Volatile/administration & dosage , Poultry , Swine , Fatty AcidsABSTRACT
O uso de promotores de crescimento na alimentação de animais tem sofrido grandes mudanças na União Européia. Empregados com sucesso há mais de 50 anos, estes aditivos foram banidos na Europa em 2006, o que intensificou as pesquisas para descobrir produtos alternativos. Já estão em uso com bons resultados na alimentação de aves, suínos e bovinos os pro-bióticos e as leveduras. Ultimamente, certos tipos de óleos demonstraram interferir na fermentação do rúmen produzindo mais ácidos gráxos.(AU)
Subject(s)
Animals , Cattle , Oils, Volatile/administration & dosage , Functional Food , Plant Oils/analysis , Growth and Development , Fatty Acids , Swine , PoultryABSTRACT
Treatment of anaemia is a very important aspect in the management of cancer patients. In order to carry out a consensus process about the use of erythropoietic stimulating agents (ESAs) in cancer patients, the Spanish Society of Medical Oncology (SEOM) elaborated a working group which coordinated a panel of medical oncology specialists. This working group has reviewed the main issues about the use of ESAs. In addition a consensus meeting was held in Madrid on 25 April 2007. The following conclusions were made: Since ESA treatment increases the haemoglobin (Hb) level and decreases the red blood cell (RBC) transfusion requirements, ESAs should be used within the approved indications in patients undergoing chemotherapy treatment, beginning at a Hb level below 11 g/dl and maintaining it around 12 g/dl, with iron supplements if necessary. Neither increasing the ESA dose in nonresponders nor the use of ESAs in the treatment of chronic cancer-related anaemia is recommended.
Subject(s)
Anemia/complications , Anemia/drug therapy , Hematinics/therapeutic use , Medical Oncology/methods , Neoplasms/complications , Antineoplastic Agents/adverse effects , Antineoplastic Agents/therapeutic use , Blood Transfusion , Chronic Disease/therapy , Clinical Trials as Topic , Erythrocytes/metabolism , Hemoglobins/metabolism , Humans , Iron/metabolism , Practice Guidelines as Topic , SpainABSTRACT
INTRODUCTION: Oral trans-mucosal fentanyl citrate (OTFC) is the one drug specifically developed for the management of breakthrough pain. This study assesses the long-term safety and efficacy of OTFC standard clinical conditions. Patients and methods. Six-month observational study performed on cancer patients with episodes of breakthrough pain. Safety was assessed by recording the advent of adverse events and efficacy by the evaluating the intensity of breakthrough pain. RESULTS: 174 cancer patients were recruited into the study. All adverse reactions reported were mild or moderate. OTFC was significantly faster (time to the commencement of pain relief: 12.7 +/- 11.4 vs 32.7 +/- 18.4 minutes; p < 0.001) and potent (post-treatment pain intensity: 3.4 +/- 1.5 vs 4.3 +/- 1.5; p < 0.001) than the previously-used drugs. CONCLUSIONS: This observational study confirms the good safety profile of OTFC as well as its effectiveness over long-term period treatment of breakthrough pain.